



free

Check out M.I.S. **database**.

On the M.I.S. website you can gain free of charge trial access to the medical innovations database and rankings in one medical speciality.

Health Technology Assessment

Ranking methods of M.I.S. are based on comprehensive HTA. M.I.S. analysts are skilled in market access, reimbursement consulting and pricing.

HTA is a **multidisciplinary process** to evaluate the social, economic, organizational and ethical issues of a health intervention or health technology. The main purpose of conducting an assessment is to inform a policy decision making.

HTA is conducted by interdisciplinary groups that use explicit analytical frameworks drawing on a variety of methods.

Due diligence

Due diligence plays a significant role in the assessment of an enterprise before it is taken over or invested in. **value analysis of company products and patents** is believed to be the most important. This must be conducted by specialists in HTA, as the evaluation of potential to achieve reimbursement and premium price directly corresponds with the portfolio of a company to be invested in.

There are many consultancy companies in the market which provide due diligence. Many certainly can assess management, organisation and financial flows but what about true value of patents owned by the company?

M.I.S. can help investors to assess innovativeness of possessed health technologies. We will be happy **to cooperate and collaborate with consulting companies** dealing with due diligence.

we identify
innovations
worth funding



MedInvest Scanner
Starowislna St. 17/3
31-038 Krakow, Poland

+48 123789579
+1 8455821595
+ 44 2033320494

✉ office@medinvestscanner.com
🌐 www.medinvestscanner.com

www.medinvestscanner.com


Welcome



MedInvest Scanner can become the first choice partner of entrepreneurial medical device producers, health care providers before they purchase modern equipment and most of all those, who aim to invest in innovative health technologies.

Our mission is to identify innovations worth funding.

In other words, M.I.S. can substantially reduce your investment risk to the level of **30-40%** with our rankings and as low as **5-10%** with Competitive Technology Reports (CTRs). Our team is highly experienced in market access, reimbursement and pricing.



MedInvest Scanner is the creator of innovative non-drug medical products database. M.I.S. constantly updates information about disruptive medical technologies which are not well disseminated yet with comparison to their potential of innovativeness.

Whereas there is much hype, only some of medical technologies deserve the name of innovation.

The M.I.S. database can save your time, as you browse only through innovative medical products assessed in accordance with EBM & HTA criteria.

You will find many of the world's cutting edge medical devices which deserve investors' attention. Technologies are presented in clear format according to disease area.

MedInvest Scanner has created the database of innovative medical devices. All of these devices were ranked according to set of criteria based on epidemiology, health technology assessment and others. Higher value of ranking points assigned to a particular technology **indicates greater attractiveness** relative to all other technologies on the market.

To derive our ranking score we assess domains such as: impact on public health, impact on individual patient's health, efficacy, safety and incremental cost-effectiveness, as compared with comparators currently available and most commonly used in health care.

Our ranking provides you with a **quick and easy-to-use** tool which will broaden your knowledge surrounding the existing competitive landscape.

One of the primary services of the M.I.S. is the provision of competitive emerging technology reports so called CTR. As a result of landscape investigation we can inform you in technologies already on the market but also in those which are **beyond the horizon.**

Within CTR MedInvest Scanner will provide you with information of expected prices of technologies entering the market, due to Value Based Pricing criteria. CTR also embraces evaluation of budget impact in a given market segment in selected countries.

The CTR contains information concerning the competitive environment and alternative market access strategies of upcoming products. Within the analyses, we assess the innovativeness of a given medical product along with its added-value compared to current and prospective treatment or diagnostic options.